|Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity.|
|PMID: 21376323 Owner: NLM Status: MEDLINE|
|INTRODUCTION: Patients with chronic kidney disease (CKD) have increased risk of cardiovascular disease to which co-morbidity and associated conventional risk factors contribute. We hypothesised that arterial stiffness (AS) and endothelial dysfunction (ED), as surrogates of cardiovascular risk, would worsen as renal function declined even in patients without co-morbidity and that this would relate to emerging cardiovascular risk factors.
METHODS: Carotid-femoral pulse wave velocity (PWV), as a measure of AS, and flow-mediated dilatation (FMD) of the brachial artery, as a measure of ED, were assessed in CKD patients without established cardiovascular disease or diabetes mellitus.
RESULTS: PWV increased linearly as renal function declined (r(2) = 0.08, p < 0.01) whereas FMD was reduced only in patients with advanced kidney disease. In multivariable analysis, blood pressure was the major determinant of PWV and FMD. High-sensitivity C-reactive protein and asymmetric dimethylarginine, and isoprostanes and endothelin-1, were independent predictors of PWV and FMD, respectively. However, renal function did not independently predict either AS or ED.
CONCLUSIONS: These findings suggest that declining renal function, in the absence of significant co-morbidity, is associated with progressive arterial stiffness, but only patients close to dialysis exhibit endothelial dysfunction. Whilst blood pressure remains the major determinant of PWV and FMD, inflammation, oxidative stress and endothelin-nitric oxide balance contribute to cardiovascular risk, in this non-comorbid cohort.
|Pajaree Lilitkarntakul; Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Barbara Liebman; Takae Asai; Jennifer Pollock; Jane Goddard; David J Webb|
Related Documents :
|8137843 - Hemodynamics and hepatic energy metabolism in canine model of acute hepatic venous occl...
18516453 - Glycol methacrylate-embedding medium to study morphological alterations of saphenous ve...
9296413 - Effects of oxygenation during selective lobar versus total lung collapse with or withou...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-03-03|
|Title: Atherosclerosis Volume: 216 ISSN: 1879-1484 ISO Abbreviation: Atherosclerosis Publication Date: 2011 May|
|Created Date: 2011-05-06 Completed Date: 2011-08-23 Revised Date: 2014-01-23|
Medline Journal Info:
|Nlm Unique ID: 0242543 Medline TA: Atherosclerosis Country: Ireland|
|Languages: eng Pagination: 217-25 Citation Subset: IM|
|Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.|
|APA/MLA Format Download EndNote Download BibTex|
Analysis of Variance
Arginine / analogs & derivatives, blood
Biological Markers / blood
Brachial Artery / physiopathology*
C-Reactive Protein / analysis
Carotid Arteries / physiopathology*
Endothelin-1 / blood
Endothelium, Vascular / physiopathology*
Femoral Artery / physiopathology*
Glomerular Filtration Rate
Isoprostanes / blood
Kidney / physiopathology
Kidney Diseases / blood, epidemiology, physiopathology*
Peripheral Arterial Disease / blood, epidemiology, physiopathology*
Scotland / epidemiology
Uremia / epidemiology, physiopathology*
|P01 HL069999/HL/NHLBI NIH HHS; PG/05/91//British Heart Foundation|
|0/Biological Markers; 0/Endothelin-1; 0/Isoprostanes; 30315-93-6/N,N-dimethylarginine; 9007-41-4/C-Reactive Protein; 94ZLA3W45F/Arginine|
|Atherosclerosis. 2011 Jun;216(2):275-6
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oncostatin M is expressed in atherosclerotic lesions: A role for Oncostatin M in the pathogenesis of...
Next Document: Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hy...